氨己烯酸片(喜保宁)在中国上市了吗

It is an irreversible GABA transaminase inhibitor that can increase the levels of GABA in the brain and cerebrospinal fluid. It was developed in the 1980s. In 1989, Vigabatrin was approved for treatment in the UK. On August 21, 2009, the U.S. FDA approved Vigabatrin for monotherapy in pediatric patients aged 1 month to 2 years, where the potential benefits of infantile spasms outweigh the potential risk of vision loss, and as an adjuvant (additional) treatment for adult patients with refractory complex partial epilepsy (CPS). On January 16, 2019, the FDA approved the launch of a generic version of Vigabatrin tablets. Vigabatrin tablets (Vigabatrin) are sold under the brand name Sabril in Canada, Mexico, and the United Kingdom.

Are vigabatrin tablets (Vigabatrin) available in China? At present, vigabatrin tablets (Vigabatrin) have not been launched in the country.

Vigabatrin tablets (Vigabatrin) are rapidly absorbed after oral administration, and food does not affect its absorption speed. The peak plasma concentration is reached 2 hours after taking the drug, and t1/2 is 5-7 hours. When a single dose is 1-3g, the pharmacokinetics show a dose-linear relationship. If the patient has special circumstances, he or she needs to inform the doctor before starting treatment with Vigabatrin, and the doctor will make adjustments to the patient's medication based on the actual situation to avoid harm to the patient due to incorrect medication.

The incidence of visual field defects is high (approximately one third) in patients taking vigabatrin tablets (Vigabatrin). This often occurs after several months to years of using vigabatrin. Visual field defects can be severe, which can have real consequences for the patient. Most patients with visual field loss have no obvious symptoms.

  The above is the introduction about it, I hope it can help everyone. If patients have other questions about the drug (such as drug price, purchasing channels, etc.), they can consult the medical companion travel service.

Recommended related hot articles: /newsDetail/84560.html